PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417

• Pau Montesinos,
• Haifa Kathrin Al-Ali,
• Juan Manuel Alonso Dominguez,
• Madlen Jentzsch,
• Mojca Lavrencic,
• Maria Paola Martelli,
• Christoph Röllig,
• Simona Sica,
• Iadevaia Riham,
• Kaitlin Yablonski,
• Tianli Wang,
• Zafar Mahmood,
• Giedre Koenen,
• Hank Schmidt,
• Jingsing Yang,
• Karen Yee

Affiliations

Pau Montesinos

1 La Fe University and Polytechnic Hospital, València, Spain

Haifa Kathrin Al-Ali

2 University Hospital Halle (Saale), Halle (Saale), Germany

Juan Manuel Alonso Dominguez

3 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

Madlen Jentzsch

4 Leipzig University, Leipzig, Germany

Mojca Lavrencic

5 Erasmus University Medical Center, Rotterdam, The Netherlands

Maria Paola Martelli

6 University of Perugia, Perugia, Italy

Christoph Röllig

7 Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Dresden, Germany

Simona Sica

8 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Iadevaia Riham

9 GSK, Waltham, United States

Kaitlin Yablonski

10 GSK, Collegeville, United States

Tianli Wang

9 GSK, Waltham, United States

Zafar Mahmood

9 GSK, Waltham, United States

Giedre Koenen

11 GSK, Zug, Switzerland

Hank Schmidt

10 GSK, Collegeville, United States

Jingsing Yang

10 GSK, Collegeville, United States

Karen Yee

12 Princess Margaret Cancer Centre, Toronto, Canada